Sassi Nir 4

4 · Indaptus Therapeutics, Inc. · Filed Apr 11, 2025

Form 4

Period: 2025-04-10

Chief Financial Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−2,500$177→ 0 total
Exercise: $72.00From: 2019-09-13Exp: 2026-09-13→ Common Stock (2,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−41$3→ 0 total
Exercise: $331.20From: 2016-03-27Exp: 2026-03-27→ Common Stock (41 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−1,125$80→ 0 total
Exercise: $610.24From: 2019-01-22Exp: 2026-01-22→ Common Stock (1,125 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−1,250$89→ 0 total
Exercise: $25.72From: 2020-09-16Exp: 2027-09-16→ Common Stock (1,250 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−500$36→ 0 total
Exercise: $357.28From: 2016-07-25Exp: 2026-07-25→ Common Stock (500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−500$36→ 0 total
Exercise: $357.28From: 2016-07-25Exp: 2026-07-25→ Common Stock (500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.07/sh−1,125$80→ 0 total
Exercise: $34.32From: 2020-02-17Exp: 2027-02-17→ Common Stock (1,125 underlying)

Footnotes (1)

[F1]The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation.

Documents

1 file